After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. The stock was recently discussed on Yahoo Finance as it revealed that Beef ‘agtech’ company Cattler launches interface with Elanco for its Benchmark program.
ELAN belongs to the Healthcare sector of the NYSE while operating in the Drug Manufacturers – Specialty & Generic industry. At the end of the last regular session, the stock closed at $15.87 and fluctuated between $15.94 as its day high and $15.62 as its day low. The current market capitalization of Elanco Animal Health Inc is $7.82B. A total of 3.62 million shares were traded on the day, compared to an average of 5.19M shares.
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, ELAN has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 23 BUYs and 24 SELLs from insiders. Insiders purchased 979,041 shares during that period but sold 399,837.
In the most recent transaction, HOOVER R DAVID bought 5,000 shares of ELAN for 9.55 per share on Mar 14. After the transaction, the Director now owns 165,000 company shares. In a previous transaction on Mar 13, HOOVER R DAVID bought 5,000 shares at 9.46 per share. ELAN shares that Director owns now total 160,000.
Among the insiders who bought shares, Simmons Jeffrey N acquired of 15,000 shares on Mar 10 at a per-share price of $9.60. This resulted in the PRESIDENT, CEO AND DIRECTOR holding 45,000 shares of ELAN after the transaction. In another insider transaction, HOOVER R DAVID bought 10,000 shares at $11.13 per share on Mar 03. Company shares held by the Director now total 155,000.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for ELAN in the last 3 months, the mean price target is $16.25 with high estimates of $20.00 and low estimates of $12.00. In terms of 52-week highs and lows, ELAN has a high of $16.08 and a low of $7.88.
As of this writing, ELAN has an earnings estimate of $Elevai Labs, Inc. per share for the current quarter. EPS was calculated based on a consensus of Elanco Animal Health Incorporat estimates, with a high estimate of $Enliven Therapeutics, Inc. per share and a lower estimate of $eGain Corporation.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. ELAN’s latest balance sheet shows that the firm has $638.00M in Cash & Short Term Investments as of fiscal 2021. There were $6.32B in debt and $1.65B in liabilities at the time. Its Book Value Per Share was $12.45, while its Total Shareholder’s Equity was $7.51B.
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ELAN is Buy with a score of 4.00.